Cargando…
P993: SETD2 IS A BONA FIDE TUMOR SUPPRESSOR IN SYSTEMIC MASTOCYTOSIS
Autores principales: | Mancini, M., Monaldi, C., De Santis, S., Papayannidis, C., Rondoni, M., Sartor, C., Bruno, S., Curti, A., Zanotti, R., Bonifacio, M., Scaffidi, L., Pagano, L., Criscuolo, M., Ciceri, F., Elena, C., Tosi, P., Valent, P., Cavo, M., Soverini, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431013/ http://dx.doi.org/10.1097/01.HS9.0000846840.40916.c0 |
Ejemplares similares
-
SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A/MDM2 axis and can be therapeutically targeted
por: Mancini, Manuela, et al.
Publicado: (2023) -
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis
por: Martinelli, G, et al.
Publicado: (2018) -
The Bona Fide Nurse
Publicado: (1919) -
Combined Inhibition of Polo-Like Kinase-1 and Wee1 as a New Therapeutic Strategy to Induce Apoptotic Cell Death in Neoplastic Mast Cells
por: Mancini, Manuela, et al.
Publicado: (2022) -
A bona fide MAP kinase
por: Oldach, Laurel
Publicado: (2022)